{
  "id": "601c13a91cb411341a00000a",
  "type": "summary",
  "question": "What is the mechanism of action of magrolimab?",
  "ideal_answer": "Magrolimab is an anti-CD47 antibody with promising results for myelodysplastic syndromes and acute myeloid leukemia.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/32038992",
    "http://www.ncbi.nlm.nih.gov/pubmed/33279177"
  ],
  "snippets": [
    {
      "text": "Magrolimab, an anti-CD47 antibody, has shown proof-of-principle of efficacy in this therapeutic class with promising early results in both higher risk myelodysplastic syndromes (MDS) and TP53 mutant acute myeloid leukemia (AML). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33279177",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In addition, initial clinical data of CD47 targeting in AML/MDS will be reviewed, and including the first-in-class anti-CD47 antibody magrolimab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32038992",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}